NSCLC(non-small cell lung cancer) is a common lung cancer (85%) in the world.
The Pinpoint Dx Lung Assay targets these patients and diagnose the effect to chemotherapy.
The Pinpoint Dx Lung Assay, launched in late January concurrent with the publication of a validation study in The Lancet demonstrating the test's utility, is available only in the US for now. Unlike many other genetic tests for NSCLC, Pinpoint's assay is targeted not at diagnosing the disease or as a companion diagnostic, but for determining which patients may benefit from chemotherapy after surgical removal of their tumors.
Pinpoint Genomics Eyes Piece of Lung Cancer Dx Market with Prognostic NSCLC Assay | GenomeWeb
I want to summarize this kit's properties.
- The Berryman, the CEO at Pinpoints, has experienced the launch of BRCAtest in the Myriad Genetics and worked in the Genentech before the starting Pinpoint.
- This kit is available for the CoDx,that means the decision of chemotherapy after surgery.
- This kit predicts the two-third of NSCLS patients, who shouldn't be treated chemotherapy.
- The sample can be allowed to use both of frozen and FFPE tissues.
- Predicted risk means the five years survival rate.
- The low risk indicates 71.4%
- The intermediate risk indicates 58.3%
- The high risk indicated 49.2%
- They starts their business in US first. Next in EU. After that in China.
- They are careful about the expansion to Chinese market, because the population with EGFR mutaion is different.
- This kit uses quantitative realtime PCR and the number of probes are 14. (included 3 control genes)
